The purpose of this study is to investigate the pharmacokinetics (PK), metabolites, route of elimination, and mass balance of BMS-986368 in healthy male participants.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
8
Specified dose on specified days
Local Institution - 0001
Madison, Wisconsin, United States
Maximum observed concentration (Cmax)
Time frame: Up to Day 15
Time of maximum observed concentration (Tmax)
Time frame: Up to Day 15
Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T))
Time frame: Up to Day 15
Total Radioactivity (TRA)
Time frame: Up to Day 30
Number of participants with Adverse Events (AEs)
Time frame: Up to Day 36
Number of participants with Serious AEs (SAEs)
Time frame: Up to Day 36
Number of participants with AEs leading to discontinuation
Time frame: Up to Day 36
Number of participants with vital sign abnormalities
Time frame: Up to Day 30
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to Day 30
Number of participants with physical examination abnormalities
Time frame: Up to Day 30
Number of participants with clinical laboratory test abnormalities
Time frame: Up to Day 30
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.